A minority of studies used the standard three-point MACE endpoint, and many tweaked their endpoints along the way.

American Association of Clinical Endocrinology (AACE) guidelines offer evidence-based recommendations for the pharmacologic ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Atherosclerotic Cardiovascular Disease (ASCVD), including conditions such as heart attacks and strokes, remains a leading ...

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

View Full Profile. Learn about our Editorial Policies. The genetic predisposition to atherosclerotic cardiovascular disease (ASCVD) constitutes half of the known risk. Specific genetic variations, ...

Their work was published in Nature Cardiovascular Research. Atherosclerotic cardiovascular disease (ASCVD) caused by atherosclerosis is one of the leading causes of death worldwide. Inflammation ...

Heart health is important all year round and can be protected by choosing an organic diet, as supported by scientific studies ...

Ohio: Once pegged as a blockbuster medicine for lowering LDL, long-acting small interfering RNA, Inclisiran failed to find ...

Some Asian, Black and Mexican American adults at low ASCVD risk continue taking baby aspirin, despite risk and clinical guidance. Similar observations were reported for those on Medicaid or ...